Transplantation Proceedings

Preface
pp. 1613-1613(1)
Authors: Khan B.D.; Ponticelli C.

New dimensions in transplantation-weaving the future
pp. 1617-1618(2)
Author: Kahan B.D.

Meeting the challenges of transplantation in the 21st century - The New Microemulsion Formulation of Cyclosporine
pp. 1619-1623(5)
Author: Bernabeu M.

Disease management in the context of renal transplantation
pp. 1624-1626(3)
Author: Moore R.

Transplantation tolerance
pp. 1627-1629(3)
Author: Sachs D.H.

Current status of xenotransplantation: research and technology
pp. 1630-1633(4)
Author: Platt J.L.

Iterative cooperative prototyping in the design of web-based transplant information systems
pp. 1634-1636(3)
Authors: Merion R.M.; Leichtman A.B.; Tsui N.; Dean J.

High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection
pp. 1639-1641(3)
Author: Kahan B.D.

Trough cyclosporine concentration variability
pp. 1642-1644(3)
Authors: Savoldi S.; Maiorca R.; Chiappini R.; Scolari F.; Sandrini S.

Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the international neoral(R) tdm advisory consensus meeting (vancouver, november 1997)1
pp. 1645-1649(5)
Authors: Keown P.; Kahan B.D.; Johnston A.; Levy G.; Dunn S.P.; Cittero F.; Grino J.M.; Hoyer P.F.; Wolf P.; Halloran Chair P.F.

Impact of intraindividual variability of drugs on therapeutic outcomes: lessons from outside transplantation
pp. 1650-1651(2)
Author: Benet L.Z.

Generic substitution for cyclosporine: what should we be looking for in new formulations? - The New Microemulsion Formulation of Cyclosporine
pp. 1652-1653(2)
Authors: Johnston A.; Holt D.W.

Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients
pp. 1654-1655(2)
Authors: Gaspari F.; Anedda M.F.; Signorini O.; Amuchastegui S.C.; Perico N.; Remuzzi G.

Variability of sandimmune pharmacokinetics in renal transplant patients
pp. 1656-1657(2)
Authors: Wingerchuk C.; Heim-Duthoy K.L.; Macres M.G.; Kasiske B.L.

Improvement of correlation between oral dose of cyclosporine and cyclosporinemia after substitution of cyclosporine standard presentation by cyclosporine microemulsion one, in 1345 patients with kidney transplantation
pp. 1658-1659(2)
Authors: Govantes M.A.G.; Ullate P.G.; Errasti P.; Fresnedo G.F.; Capdevila L.; Guajardo A.S.; Cubero J.J.

Study of neoral kinetics in adult renal transplantation treated with diltiazem
pp. 1660-1662(3)
Authors: Mezzano S.; Flores C.; Ardiles L.; Foradori A.; Elberg A.

Pharmacokinetic studies of oral and intravenous cyclosporine in prekidney transplant patient
pp. 1663-1663(1)
Authors: Wacke R.; Bast R.; Rohde B.; Prall F.; Seiter H.; Drewelow B.

Relative bioavailability of neoral versus sandimmune in the presence of a p450iiia and p-glycoprotein inhibitor
pp. 1664-1665(2)
Authors: Choc M.G.; Mueller E.A.; Robinson W.T.; Kumle A.; Smith H.T.; Charnick S.B.

A critical appraisal of cyclosporine a pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (neoral)
pp. 1666-1667(2)
Authors: Foradori A.; Pinto V.M.; Elberg A.

The pharmacokinetics of oral cyclosporin a (neoral) during the first month after bone marrow transplantation
pp. 1668-1670(3)
Authors: Schultz K.R.; Nevill T.J.; Toze C.L.; Corr T.; Currie C.; Strong D.K.; Keown P.A.

Early cyclosporine blood levels impact the incidence of acute rejection and overall mortality in the first year after heart transplantation
pp. 1671-1672(2)
Authors: Gomez-Sanchez .A.; Delgado J.F.; Escribano P.; Santos M.; Sotelo T.; Gil R.; Hernandez-Afonso J.; Ortuno B.; Romero F.; Saenz de la Calzada C.; Rodriguez J.E.; Rufilanchas J.J.

Optimization of cyclosporine therapy in kidney transplantation
pp. 1673-1676(4)
Authors: Remuzzi G.; Perico N.; Gaspari F.

Sandimmun and neoral treatment: pharmacokinetics and kidney function in paediatric and adolescent renal transplant
pp. 1677-1677(1)
Authors: De Palma M.T.; Giordano M.; Colella V.; Palumbo F.; De Nicolo V.E.; Caringella D.A.

Area under the concentration curve values in pediatric liver transplant recipients on cyclosporin microemulsion formulation
pp. 1678-1679(2)
Authors: Dunn .P.; Kulinsky .; Falkenstein K.; Pierson A.; Chang C.T.; Cooney G.F.

Population pharmacokinetics of cyclosporine : influence of covariables and assessment of cyclosporine absorption in kidney, lung, heart and heart + lung transplanted patients
pp. 1680-1680(1)
Authors: Kyhl L.-E.B.; Rasmussen S.N.; Aarons L.; Jensen S.B.

Early achievement of target cyclosporine levels during initial post-transplant period with a novel dosing strategy
pp. 1681-1682(2)
Authors: Chueh S.-C.; Lai M.-K.

High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome
pp. 1683-1684(2)
Authors: Cicciarelli J.; Avila D.; Iwaki Y.; Sather H.; Mendez R.

Modification of the pharmacokinetics of cyclosporine a and metabolites by the concomitant use of neoral and diltiazem or ketoconazol in stable adult kidney transplants
pp. 1685-1687(3)
Authors: Foradori A.; Mezzano S.; Videla C.; Pefaur J.; Elberg A.

Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation
pp. 1688-1690(3)
Authors: Citterio F.; Torricelli P.; Serino F.; Foco M.; Pozzetto U.; Fioravanti P.; Castagneto M.

Improving the oral absorption of cyclosporine in malabsorbers: a review of the neoral compassionate need program
pp. 1691-1693(3)
Authors: Mueller E.A.; Kovarik J.M.; Pittrow D.

Cyclosporine microemulsion formulation (neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships
pp. 1694-1696(3)
Authors: Mueller E.A.; Niese D.; Mellein B.

Evaluation of the safety and tolerability of neoral and sandimmune: a meta-analysis
pp. 1697-1700(4)
Authors: Shah M.B.; Martin J.E.; Schroeder T.J.; First M.R.

Conversion of stable renal transplant recipients from sandimmune to sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method
pp. 1701-1705(5)
Authors: First M.R.; Weiskittel P.; Burton M.; Shah M.; Dreyer D.; Fleck P.; Bey C.; Peddi R.; Canafax D.; Schroeder T.J.

12th quality assessment of cyclosporin blood monitoring by 56 japanese laboratories
pp. 1706-1708(3)
Authors: Takagi H.; Uchida K.; Takahara S.; Takahashi K.

Disease management in the context of renal transplantation
pp. 1709-1711(3)
Author: Moore R.

Cyclosporine: the principal immunosuppressant for renal transplantation
pp. 1712-1715(4)
Authors: Keown P.A.; Primmett D.R.

Relationship between maintenance dose of cyclosporine and long-term kidney graft survival
pp. 1716-1717(2)
Author: Opelz G.

Optimization of cyclosporine therapy in renal transplantation
pp. 1718-1720(3)
Author: Ponticelli C.

Lessons from the neoral global database
pp. 1721-1722(2)
Author: Helderman J.H.

Management issues in renal transplantation
pp. 1723-1725(3)
Author: Loertscher R.

Early histopathologic changes predicting long-term kidney transplant survival
pp. 1726-1728(3)
Authors: Savoldi S.; Scolari F.; Sandrini S.; Tardanico R.; Morassi L.; Zubani R.; Bossini N.; Viola B.F.; Maiorca R.

A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation: results at 7 years
pp. 1729-1731(3)
Authors: Tarantino A.; Segoloni G.P.; Cambi V.; Rizzo G.; Altieri P.; Mastrangelo F.; Castagneto M.; Salvadori M.; Valente U.; Cossu M.; Federico S.; Pisani F.; Montagnino G.; Messina M.; Arisi L.; Carmellini M.; Piredda G.B.; Ponticelli C.

Pregnancy outcomes in female renal transplant recipients
pp. 1732-1734(3)
Authors: Armenti V.T.; McGrory C.H.; Cater J.R.; Radomski J.S.; Moritz M.J.

Effect of HLA matching on cadaver kidney survival in the north italy transplant program
pp. 1735-1738(4)
Authors: Sirchia G.; Poli F.; Cardillo M.; Rebulla P.; Taioli E.; Scalamogna M.

Survival probabilities for renal transplant recipients and dialytic patients: a single center prospective study
pp. 1739-1741(3)
Authors: Segoloni G.P.; Messina M.; Tognarelli G.; Damiani D.; Fop F.; Stratta P.; Piccoli G.

Renal recipients of haploidentical living donors treated with neoral or conventional cyclosporine: a comparative follow-up of 3 years
pp. 1742-1743(2)
Authors: Gracida C.; Melchor J.L.

Cyclosporine: has it made a difference between using HLA or not? a comparative study between patients with and without HLA matching
pp. 1744-1745(2)
Authors: Juarez F.; Barrios Y.; Cano L.; Chavez E.; Camacho R.; Gomez A.; Maciel M.; Borjon S.; Limones M.; Peniche L.

Safety and efficacy of conversion from once daily sandimmun to twice daily neoral cyclosporine in renal allograft recipients
pp. 1746-1748(3)
Authors: Vathsala A.; Lee W.T.; Lu Y.-M.; Woo K.T.

Neoral versus sandimmune in kidney transplantation
pp. 1749-1750(2)
Authors: Tisone G.; Orlando G.; Mercadante E.; Vennarecci G.; Pisani F.; Buonomo O.; Negrini S.; Casciani C.U.

Long-term results of kidney grafts surviving beyond the first year: comparison of cyclosporine-based regimens with the azathioprine and steroid regimen
pp. 1751-1752(2)
Authors: Rizzolo M.; Puggia R.; Maresca M.-C.; Calconi G.; Vianello A.

Conversion from sandimmune to neoral in renal transplant recipients: two-year experience
pp. 1753-1755(3)
Authors: Wilczek H.E.; &unknown;9kesson P.; Warholm C.

Conversion from sandimmune to neoral in renal transplant: functional histopathological, and pharmacokinetic changes
pp. 1756-1757(2)
Authors: Roessler E.; Herrera S.; Espinoza M.; Ayala A.; Reynolds E.; Gonzalez F.; Espinoza O.; Undurraga A.; Munoz R.; Arcos O.; Galaz G.

Neoral reduces the incidence of acute rejection after renal transplantation
pp. 1758-1759(2)
Authors: Sandrini S.; Setti G.; Gaggia P.; Chiappini R.; Maffeis R.; Tardanico R.; Maiorca R.

Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine
pp. 1760-1761(2)
Authors: Jirasiritham S.; Sumethkul V.; Mavichak V.; Jirasiritham S.

Conversion to cyclosporine microemulsion (neoral) in stable renal transplant patients: results from a single center
pp. 1762-1763(2)
Authors: Cossu M.; Satta R.; Branca G.F.; Pala P.G.; Serra G.; Satta R.P.; Sorba G.

Conventional versus neoral cyclosporine in renal transplantation
pp. 1764-1765(2)
Authors: Rovelli E.; Bucci A.; Maldifassi P.; Belfiore A.; D'Amico G.

Acute rejection is a major risk factor for chronic rejection
pp. 1766-1768(3)
Author: Matas A.J.

Flow cytometry crossmatch: a sensitive technique for assessment of acute rejection in renal transplantation
pp. 1769-1771(3)
Authors: Piazza A.; Adorno D.; Poggi E.; Borrelli L.; Buonomo O.; Pisani F.; Valeri M.; Torlone N.; Camplone C.; Monaco P.I.; Fraboni D.; Casciani C.U.

Impact of humoral alloreactivity on the survival of renal allografts
pp. 1772-1772(1)
Authors: Kluth-Pepper B.; Schneeberger H.; Lederer S.R.; Albert E.; Land W.; Feucht H.E.

Drug monitoring of mycophenolic acid in the early period after renal transplantation
pp. 1773-1774(2)
Authors: Krumme B.; Wollenberg K.; Kirste G.; Schollmeyer P.

Effect of acute rejection episodes on long-term renal graft survival
pp. 1775-1775(1)
Authors: Berczi C.; Asztalos L.; Kincses Z.; Locsey L.; Balazs G.

The effect of delayed graft function and early graft rejection on renal transplant outcome
pp. 1776-1777(2)
Authors: Marcen R.; Pascual J.; Orofino L.; de la Cal M.A.; Teruel J.L.; Villafruela J.J.; Rivera M.E.; Burgos F.J.; Mampaso F.; Ortuno J.

Antibody therapy in steroid-resistant rejection
pp. 1778-1779(2)
Authors: Waiser J.; Budde K.; Schreiber M.; Bohler T.; Lobermann L.-A.; Neumayer H.-H.

Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation
pp. 1780-1781(2)
Authors: Budde K.; Smettan S.; Fritsche L.; Waiser J.; Giessing M.; Kunz R.; Turk I.; Bauer S.; Mai I.; Neumayer H.-H.

Withdrawal of steroids from a cyclosporine-based regimen: pro
pp. 1782-1784(3)
Author: Ponticelli C.

Steroid withdrawal from cyclosporine-based regimens: con-a flawed strategy
pp. 1785-1787(3)
Authors: Hricik D.E.; Schulak J.A.

Long-term outcome of kidney transplantation after steroid withdrawal
pp. 1788-1789(2)
Authors: Dunn T.; Asolati M.; Holman D.; Raofi V.; Lutrin F.; Massad M.; Pollak R.; Benedetti E.

Effect of antithymocyte globulin induction treatment on renal transplant outcome
pp. 1790-1792(3)
Authors: Sanchez-Fructuoso A.I.; Naranjo P.; Torrente J.; Fernandez-Perez C.; Aviles B.; Prats D.; Barrientos A.

Renal transplantation from older donors: a single center experience
pp. 1793-1794(2)
Authors: Sanchez-Fructuoso A.I.; Prats D.; Naranjo P.; Fernandez C.; Aviles B.; Barrientos A.

Long-term results after stopping cyclosporine at 6 months following renal transplantation
pp. 1795-1795(1)
Authors: Michalowski K.; Pontin A.R.; Pascoe M.D.; Kahn D.

Long-term renal graft failure declines with only azathioprine/steroid immunosuppression
pp. 1796-1797(2)
Authors: Baltzan Sr M.A.; Shoker A.S.; Dyck R.F.; Baltzan Jr M.A.

Renal transplantation for systemic lupus erythematosis: excellent long-term results with both living and cadaveric donors
pp. 1798-1799(2)
Authors: Magee J.C.; Leichtman A.B.; Merion R.M.

Arteriotomy using the aortic punch in kidney transplantation
pp. 1800-1800(1)
Authors: Hakim N.S.; Papalois V.E.; Romagnoli J.

The impact of induction therapy hla matching and t- and b-cell crossmatch on the long-term outcome of living donated renal transplantation
pp. 1801-1804(4)
Authors: Lumlertgul D.; Manoyos A.; Saikum U.; Chaovisitsaree A.; Boonkaew S.; Wongsawad P.; Bunnachak D.; Roachanapiwat B.; Wutikarn S.

Factors affecting long-term renal allograft survival in cyclosporine-treated kidney transplants
pp. 1805-1809(5)
Authors: Tanabe K.; Ishikawa N.; Tokumoto T.; Takahashi K.; Oshima T.; Fuchinoue S.; Toma H.

Factors influencing renal transplantation in a developing country
pp. 1810-1811(2)
Authors: Rizvi S.A.H.; Naqvi S.A.A.; Hussain Z.; Hafiz S.; Akhtar F.; Zafar N.; Altaf H.; Ahmed E.; Hussain M.

Neoral is superior to FK 506 in liver transplantation
pp. 1812-1815(4)
Author: Levy G.A.

Optimization of cyclosporine therapy in liver transplantation
pp. 1816-1818(3)
Authors: Pollard S.G.; Lodge J.P.A.

Liver transplantation: changing goals in immunosuppression
pp. 1819-1821(3)
Authors: McMaster P.; Gunson B.; Min X.; Afonso R.; Bastos J.

Trends in liver transplantation: hepatocellular cancer and alcoholic liver disease
pp. 1822-1825(4)
Author: Wall W.J.

Importance of cyclosporine pharmacokinetics to clinical outcomes after liver transplantation
pp. 1826-1827(2)

High-rate hepatitis and low-rate rejection induced late morbidity and mortality in long-term follow-up after liver transplantation
pp. 1828-1829(2)
Authors: Caccamo L.; Rossi G.; Gridelli B.; Maggi U.; Reggiani P.; Colledan M.; Fassati L.R.

Impact of sandimmune, neoral, and prograf on rejection incidence and renal function in primary liver transplant recipients
pp. 1830-1832(3)
Authors: Van Buren D.; Payne J.; Geevarghese S.; MacDonell R.; Chapman W.; Wright J.K.; Helderman J.H.; Richie R.; Pinson C.W.

Improvement in correlation between oral dose of cyclosporine and cyclosporinemia after substitution of conventional cyclosporine by neoral cyclosporine in 296 liver transplant patients
pp. 1833-1837(5)
Authors: Bilbao I.; Parrilla P.; Rimola A.; Figueras J.; Fabrega E.; Gomez M.; De Vicente E.; Margarit C.

Economic evaluation of neoral versus sandimmune maintenance therapy for de novo liver transplant patients: results from an international randomized controlled trial - Practice and Management
pp. 1838-1842(5)
Authors: Peeters P.; Kazek M.; Abella I.; Noble I.

Liver transplantation for end-stage liver disease related to viral hepatitis
pp. 1843-1845(3)
Authors: Tisone G.; Angelico M.; Vennarecci G.; Palmieri G.; Orlando G.; Iaria G.; Baiocchi L.; Casciani C.U.

Distribution of lymphocyte subtypes in liver transplant recipients with viral reinfection or de novo malignancy
pp. 1846-1847(2)
Authors: Rayes N.; Bechstein W.O.; Tullius S.G.; Nussler N.C.; Naumann U.; Jonas S.; Neuhaus R.; Serke S.; Neuhaus P.

Microemulsion cyclosporine (neoral) immunosuppression for orthotopic liver transplantation in children reduces hospital stay
pp. 1848-1849(2)
Authors: Arumugam R.; Soriano H.E.; Scheimann A.O.; Reid B.S.; Gopalakrishna G.S.; Barakat O.; Ozaki C.F.; Wood R.P.

Perihepatic packing in liver transplantation
pp. 1850-1851(2)
Authors: Xu M.; Bastos J.; Dmitrewski J.; Okajima H.; Gunson B.; Pirenne J.; Buckels J.; McMaster P.; Mayer D.

Safety of conversion from cyclosporine sandimmune to cyclosporine neoral in stable liver transplant patients
pp. 1852-1853(2)
Authors: Baruch Y.; Assy N.; Kramsky R.; Enat R.

Low incidence of acute cellular rejection in liver transplantation with neoral
pp. 1854-1854(1)
Authors: Imventarza O.; Lendoire J.; Bianco G.; Saul J.; Braslavsky G.; Trigo P.; Cueto G.; Duek F.; Aziz H.

Reduced acute rejection after liver transplantation with neoral-based double immunosuppression
pp. 1855-1856(2)
Authors: Reggiani P.; Rossi G.; Latham L.; Caccamo L.; Gatti S.; Maggi U.; Melada E.; Paone G.; Doglia M.; Vannelli A.; Fassati L.R.

Conversion from the conventional cyclosporine formulation (sandimmune) to a new oral microemulsion (neoral) in stable liver transplant patients
pp. 1857-1857(1)
Authors: Dibo-Cohen J.M.; Conort O.; Conti F.; Bernard D.; Hazebroucq G.; Calmus Y.

Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation
pp. 1858-1860(3)
Authors: Alberti D.; Reding R.; Otte J.B.; Falchetti D.; Rigamonti W.; Caccia G.; Sokal E.; de Ville de Goyet J.

Frequency of switch from cyclosporine to fk 506 before and after neoral use in pediatric liver transplantation
pp. 1861-1862(2)
Authors: Gridelli B.; Colledan M.; Lucianetti A.; Ulla L.; Riva S.; Segalin A.; Fassati L.R.; Torre G.

Disappearance of diabetes mellitus after conversion from fk 506 to neoral in two liver transplanted patients
pp. 1863-1864(2)
Authors: Lagget M.; Marzano A.; Actis G.C.; Leone N.; Ciancio A.; Salizzoni M.; Rizzetto M.

Combined liver-kidney transplantation: long-term follow-up in 18 patients
pp. 1865-1867(3)
Authors: Lang M.; Kahl A.; Bechstein W.O.; Neumann U.; Settmacher U.; Frei U.; Neuhaus P.

Effect of liver transplantation in cirrhotic diabetic patients
pp. 1868-1868(1)
Authors: Perseghin G.; Baratti D.; Benedini S.; Regalia E.; Mazzaferro V.; Luzi L.

Treatment with pge₁ in patients after liver transplantation
pp. 1869-1870(2)
Authors: Neumann U.P.; Kaisers U.; Langrehr J.M.; Lang M.; Glanemann M.; Raakow R.; Steinmuller T.; Settmacher U.; Muller A.R.; Bechstein W.O.; Neuhaus P.

Veno-venous bypass versus no bypass in orthotopic liver transplantation: hemodynamic, metabolic, and renal data
pp. 1871-1873(3)
Authors: Rossi G.; Langer M.; Maggi U.; Reggiani P.; Caccamo L.; Gatti S.; Paone G.; Vannelli A.; Prato P.; Doglia M.; Melada E.; Latham L.; Fassati L.R.

Incidence and risk factors of prolonged mechanical ventilation and causes of reintubation after liver transplantation
pp. 1874-1875(2)
Authors: Glanemann M.; Langrehr J.M.; Muller A.R.; Platz K.P.; Guckelberger O.; Stange B.; Neumann U.; Raakow R.; Keck H.; Settmacher U.; Bechstein W.O.; Neuhaus P.

Late orthotopic liver retransplantation: indications and survival
pp. 1876-1877(2)
Authors: Duran F.G.; Cercadillo R.A.; Santos L.; de Diego A.; Ferreiroa J.; Valdecantos E.; Clemente G.

In situ liver splitting of cadaveric donors: four cases of italian experience
pp. 1878-1880(3)
Authors: Andorno E.; Antonucci A.; Valente R.; Vertocchi M.; Dardano G.; Morelli N.; Ermili F.; Mondello R.; Paraluppi G.; Ardizzone G.; Colledan M.; Gridelli B.; Lucianetti A.; Valente U.

Cyclosporine heart transplantation
pp. 1881-1884(4)
Authors: Cheung A.; Menkis A.H.

Cardiac transplantation: three decades of experience define our challenge
pp. 1885-1888(4)
Author: Young J.B.

Long-term persistence of lung function abnormalities after heart transplantation
pp. 1889-1891(3)
Authors: Ewert R.; Walde T.; Bettmann M.; Wensel R.; Bauer U.; Kleber F.-X.; Hetzer R.

Comparative bioavailability of neoral and sandimmune in cardiac transplant recipients over 1 year
pp. 1892-1894(3)
Authors: Cooney G.F.; Jeevanandam V.; Choudhury S.; Feutren G.; Mueller E.A.; Eisen H.J.

Conversion from standard cyclosporine to neoral in lung transplant recipients
pp. 1895-1897(3)
Authors: Kesten S.; Scavuzzo M.; Laurin L.; Tan A.; Chaparro C.

Neoral conversion in stable thoracic transplant patients leads to dose reduction 1
pp. 1898-1899(2)
Authors: Zaldonis D.B.; Keenan R.J.; Pham S.M.; Kormos R.L.; Griffith B.P.

Clinical impact of neoral in thoracic organ transplantation
pp. 1900-1903(4)
Authors: Aziz T.; El-Gamel A.; Keevil B.; Krysiak P.; Campbell C.; Rahman A.; Deiraniya A.; Yonan N.

Neoral versus sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation
pp. 1904-1905(2)
Authors: Maccherini M.; Bernazzali S.; Diciolla F.; Giunti G.; Bizzarri F.; Lisi G.F.; Davoli G.; Biagioli B.; Giomarelli P.P.; Simeone F.; Caciorgna M.; Marchetti L.; Pula G.; Sani G.; Toscano M.

Long-term safety and efficacy of neoral in heart transplantation
pp. 1906-1909(4)
Authors: Yonan N.A.; Aziz T.; El-Gamel A.; Campbell C.S.; Rahman A.N.; Deiraniya A.K.

Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis
pp. 1910-1911(2)
Authors: Dosanjh A.K.; Wan B.; Throndset W.; Sherwood S.; Morris R.E.

Risk factors for early mortality, acute rejection, and factors affecting first-year survival after heart transplantation
pp. 1912-1914(3)
Authors: Aziz T.; El-Gamel A.; Krysiak P.; Rahman A.; Campbell C.; Yonan N.; Deiraniya A.

Ten year experience in orthotopic heart transplantation: single center result
pp. 1915-1916(2)
Authors: Aziz T.; El-Gamel A.; Krysiak P.; Rahman A.; Campbell C.; Yonan N.; Deiraniya A.

Implication of HLA mismatch in the clinical outcome of orthotopic heart transplantation
pp. 1917-1919(3)
Authors: Aziz T.M.; Sheldon S.; El-Gamel A.; Krysiak P.; Campbell C.; Rahman A.; Dyer P.; Yonan N.; Deiraniya A.

Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine a
pp. 1920-1921(2)
Authors: Behr T.M.; Richter K.; Fischer P.; Spes C.H.; Meiser B.; Reichart B.; Pongratz D.; Feucht H.; Theisen K.; Angermann C.E.

Multiple coronary thrombosis and allograft vascular disease
pp. 1922-1924(3)
Authors: Arbustini E.; Dal Bello B.; Morbini P.; Gavazzi A.; Specchia G.; Vigano M.

Impact of noninvasive diagnostic methods on the incidence and prognosis of cardiac allograft rejection
pp. 1925-1925(1)
Authors: Grauhan O.; Knosalla C.; Muller J.; Spiegelsberger S.; Moller J.; Bettmann M.; Thompson L.; Jonas S.; Loebe M.; Hummel M.; Ewert R.; Hetzer R.

Assessment of intraindividual variability of coronary flow reserve in angiographically normal coronary arteries in transplant recipients: a study with intracoronary doppler and intravascular ultrasound
pp. 1926-1927(2)
Authors: Rieber J.; Klauss V.; Konig A.; Henneke K.H.; Spes C.; Regar E.; Werner F.; Meiser B.; Reichart B.; Theisen K.; Mudra H.

Heart transplantation in patients with neoplastic disease
pp. 1928-1928(1)
Authors: Caforio A.L.P.; Tursi V.; Brombin M.; Feltrin G.; Angelini A.; Livi U.

Rejection pattern of cardiac and skeletal muscle allografts: implications for surveillance of cardiac rejection
pp. 1929-1929(1)
Authors: Benedetti E.; Blanchard J.; Sekosan M.; Raofi V.; Dunn T.; Lutrin F.; Massad M.

Heart rate variability, exercise capacity, and o₂ uptake kinetics in heart transplant recipients
pp. 1930-1931(2)
Authors: Mettauer B.; Fouillot J.-P.; Epailly E.; Zhao Q.-M.; Charloux A.; Lampert E.; Heitz-Naegelen B.; Rieu M.; Lonsdorfer J.

Primary graft failure in heart transplantation: a multivariate analysis
pp. 1932-1932(1)
Authors: Segovia J.; Pulpon L.A.; Sanmartn M.; Tejero C.; Serrano S.; Burgos R.; Castedo E.; Ugarte J.

Detection and prediction of acute heart transplant rejection: preliminary results on the clinical use of a ''black blood'' magnetic resonance imaging sequence
pp. 1933-1935(3)
Authors: Marie P.Y.; Carteaux J.P.; Angio M.; Marwan N.S.; Tzvetanov K.; Escanye J.M.; David N.; Mattei S.; Danchin N.; Karcher G.; Bertrand A.; Villemot J.P.

Insulin independence for more than 10 years after pancreas transplantation
pp. 1936-1937(2)
Authors: Najarian J.S.; Gruessner A.C.; Drangsteveit M.B.; Gruessner R.W.G.; Goetz F.C.; Sutherland D.E.R.

Outcome of kidney transplantation alone versus synchronous pancreas-kidney transplantion in type 1 diabetics
pp. 1938-1939(2)
Authors: Cattral M.S.; Hemming A.W.; Greig P.D.; Rowsell C.; Chari R.; Cole E.; Donat D.; Wright E.; Levy G.A.

Pancreas transplantation: a review
pp. 1940-1943(4)
Authors: Sutherland D.E.R.; Gruessner A.C.; Gruessner R.W.G.

Clinical use of the euglycemic hyperinsulinemic clamp for diagnosis of tacrolimus-induced insulin resistance after combined pancreas-kidney transplantation
pp. 1944-1945(2)
Authors: Berweck S.; Kahl A.; Bechstein W.; Platz K.; Muller U.; Neuhaus P.; Frei U.

Low incidence of rejection after synchronous pancreas-kidney transplantation with neoral
pp. 1946-1946(1)
Authors: Cattral M.S.; Hemming A.W.; Greig P.D.; Rowsell C.; Chari R.; Wright E.; Donat D.; Cole E.; Levy G.A.

Impact of kidney-pancreas transplantation on the progression of peripheral vascular disease in diabetic patients with end-stage renal disease
pp. 1947-1949(3)
Authors: Knight R.J.; Schanzer H.; Guy S.; Fishbein T.; Burrows L.; Miller C.

Efficacy of SH U 508 A (levovist) in color doppler imaging of pancreatic grafts
pp. 1950-1951(2)
Authors: Torraco A.; Tomasella G.; Baldan N.; Codello L.; Parise P.; Marchini F.; Rigotti P.

Pediatric organ transplantation
pp. 1952-1955(4)
Author: Harmon W.

New immunosuppressive agents in pediatric renal transplantation
pp. 1956-1958(3)
Author: Ettenger R.B.

Growth following renal transplantation in children
pp. 1959-1960(2)
Authors: Fine R.N.; Tejani A.

NOF-11: A one-year randomized double-blind comparison of neoral versus sandimmune in pediatric liver transplantation
pp. 1961-1961(1)
Authors: Alvarez F.; Atkison P.; Grant D.; Jones A.; Kim P.; Kneteman N.; Laurin L.; Martin S.; Paradis K.; Shapiro J.; Smith L.; Superina R.; Tan A.

Results of conversion from sandimmune to neoral in stable pediatric liver transplant recipients after two years
pp. 1962-1963(2)
Authors: Dunn S.P.; Falkenstein K.; Pierson A.; Cooney G.F.

Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient
pp. 1964-1966(3)
Authors: Falkenstein K.; Dunn S.

Twelve years of cyclosporine in pediatric heart transplantation: what is the future?
pp. 1967-1968(2)
Authors: Parisi F.; Abbattista A.D.; Squitieri C.; Vinciguerra G.; La Vigna G.; Di Donato R.; Catena G.

Growth acceleration on cyclosporine monotherapy after liver transplantation in children
pp. 1969-1972(4)
Authors: Falkenstein K.; Dunn S.

Neoral cyclosporine as maintenance immunosuppression in pediatric small bowel transplantation
pp. 1973-1974(2)
Authors: Atkison P.; Williams S.; Howard J.; Wall W.; Paradis K.; Seidman E.; Grant D.

Cyclosporine-based steroid-free therapy in pediatric heart transplantation: long-term results
pp. 1975-1976(2)
Authors: Livi U.; Caforio A.L.P.; Gambino A.; Tursi V.; Milanesi O.; Stellin G.; Angelini A.; Casarotto D.

Twenty-six year surgical experience of 259 pediatric transplants in 235 children and long-term follow-up of 181 under cyclosporine therapy
pp. 1977-1979(3)
Authors: Berardinelli L.; Ferraresso M.; Raiteri M.; Carini M.; Vegeto A.

Effect of variability of cyclosporine pharmacokinetics on long-term renal allograft survival
pp. 1980-1982(3)
Authors: Markell M.S.; Homel P.; Sumrani N.; Hong J.H.; Distant D.A.; Miles A.-M.V.; Sommer B.G.; Friedman E.A.

Estimated area-under-the-curve monitoring of neoral in a stable pediatric renal transplant population: one-year experience
pp. 1983-1984(2)
Authors: Lemire J.; Capparelli E.V.; MacDonald D.; Benador N.; Reznik V.M.; Mendoza S.A.; Griswold W.R.

Pharmacokinetics of oral cyclosporine microemulsion formulation (neoral) in children awaiting renal transplantation
pp. 1985-1987(3)
Authors: Gusmano R.; Basile G.C.; Perfumo F.; Ginevri F.; Verrina E.; Famularo L.; Corbetta G.

Pharmacokinetic study of twice vs thrice daily dosing of sandimmun neoral in pediatric renal transplant patients - A New Formulation of Ciclosporine
pp. 1988-1990(3)
Authors: Papachristou F.; Gakis D.; Sotiriou I.; Liatsis I.; Takoudas D.; Antoniadis A.

Monitoring of renal function in children before and after liver transplantation
pp. 1991-1992(2)
Authors: Vajro P.; Pecoraro C.; De Vincenzo A.; Genovese E.; Silvestre C.; Brancato T.; Migliaro F.

Liver transplantation in children for metabolic diseases
pp. 1993-1994(2)
Authors: Arumugam R.; Soriano H.E.; Scheimann A.O.; Reid B.S.; Gopalakrishna G.S.; Barakat O.; Ozaki C.F.; Wood R.P.

Sandimmun-to-neoral conversion in stable pediatric kidney transplant recipients
pp. 1995-1996(2)
Authors: Kelles A.; Herman J.; Tjandra-Maga T.B.; Van Damme-Lombaerts R.

Transplantation issues in pediatric retinal-renal syndromes
pp. 1997-1999(3)
Authors: Acott P.D.; McLellan D.H.; Wade A.W.; McDonald A.T.J.; Crocker J.F.S.

Impact of vesicoureteral reflux on graft survival in paediatric kidney transplants
pp. 2000-2001(2)
Authors: Fontana I.; Ginevri F.; Arcuri V.; Basile G.; Nocera A.; Beatini M.; Barocci S.; Tommasi G.V.; Bonato L.; Casolino V.; Valente R.; Gusmano R.; Valente U.

Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients
pp. 2002-2005(4)
Authors: Crocker J.; Renton K.; Wade A.; McLellan H.; Acott P.

Posttransplant hypertension
pp. 2009-2011(3)
Author: Curtis J.J.

ecNOS overexpression in CsA-treated renal transplant patients: implications for CsA-induced hypertension
pp. 2012-2013(2)
Authors: Calo L.; Davis P.A.; Rigotti P.; Milani M.; Cantaro S.; Marchini F.; D'Angelo A.; Antonello A.

Role of p-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin ii deposits
pp. 2014-2016(3)
Authors: Del Moral R.G.; Olmo A.; Osuna A.; Aguilar M.; Carvia R.; Becerra P.; Arrebola F.; Guillen M.; Reguero M.E.; Asensio C.; O'Valle F.

Hepatocyte growth factor: a sensitive indicator for csa-induced nephropathy
pp. 2017-2018(2)
Authors: Yoshimura R.; Kasai S.; Sugimura K.; Wada S.; Yoshimura N.; Yamamoto K.; Kishimoto T.

Role of insulinlike growth factor I in renal transplantation: evaluation of intra- and postoperative effects
pp. 2019-2023(5)
Authors: Maestri M.; Adams G.; Gaspari A.; Passalia L.; Innocente F.; Rademacher J.; Luzzana F.; Polese M.; Bolla E.; Noli S.; Scotti-Foglieni A.; Scotti-Foglieni C.; Dafoe D.; Dionigi P.; Zonta A.; Rabkin R.

Nonmuscle and smooth muscle myosin heavy-chain expression in rat renal allografts
pp. 2024-2025(2)
Authors: Watanabe Y.; Yoshimura R.; Wada S.; Suzuki J.; Ohyama A.; Kishimoto T.; Isobe M.

Acute cya-induced atp depletion is prevented by pretreatment with l-propionylcarnitine in isolated and perfused rat kidney
pp. 2026-2027(2)
Authors: Giovannini L.; Migliori M.; Taccola D.; Panichi V.; Andreini B.; De Pietro S.; Filippi C.; Palla R.

Verapamil prevents cyclosporine-induced hypertension by modulating endothelin a receptor expression in rat kidney membranes
pp. 2028-2029(2)
Authors: Giovannini L.; Migliori M.; Taccola D.; Panichi V.; Andreini B.; De Pietro S.; Filippi C.; Del Ry S.; Andreassi M.G.; Colombo M.G.; Biagini A.; Giannessi D.; Palla R.

Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients
pp. 2030-2032(3)
Authors: Burrows L.; Knight R.; Genyk Y.; Schwartz B.; Moran V.; Anand R.

Behavioral conditioning prolongs heart allograft survival in rats
pp. 2033-2033(1)
Authors: Exton M.S.; Schult M.; Donath S.; Strubel T.; Nagel E.; Westermann J.; Schedlowski M.

Imipenem/cilastatin reduces cyclosporin-induced tubular damage in kidney transplant recipients
pp. 2034-2035(2)
Authors: Carmellini M.; Matteucci E.; Boggi U.; Cecconi S.; Giampietro O.; Mosca F.

Tubular damage and impairment of renal function in transplanted kidneys
pp. 2036-2037(2)
Authors: Donadio C.; Puccini R.; Lucchesi A.; Giordani R.; Rizzo G.

Rupture of the transplanted kidney: a clinicopathologic study of 37 nephrectomy cases
pp. 2038-2038(1)
Authors: Szederkenyi E.; Ivanyi B.; Smehak G.; Morvay Z.; Szenohradszky P.; Marofka F.; Ormos J.

Cardiovascular complications after renal transplantation
pp. 2039-2042(4)
Authors: Aker S.; Ivens K.; Guo Z.; Grabensee B.; Heering P.

Oxidizability of low-density lipoproteins from neoral and tacrolimus-treated renal transplant patients
pp. 2043-2046(4)
Authors: Varghese Z.; Fernando R.L.; Turakhia G.; Psimenou E.; Brunton C.; Fernando O.N.; Davenport A.; Burns A.; Sweny P.; Powis S.H.; Moorhead J.F.

Risk factors for cardiovascular disease in patients with functioning kidney grafts
pp. 2047-2047(1)
Authors: Lorenzetti M.; Giannarelli R.; Paleologo G.; Rizzo G.; Marchetti P.; Coppelli A.; Innocenti M.; Rindi P.; Carmellini M.; Mosca F.; Marselli L.; Lencioni C.; Di Cianni G.; Navalesi R.

Evaluation of lipoprotein A in renal transplant recipients
pp. 2048-2048(1)
Authors: Innocenti M.; Lorenzetti M.; Naldi F.; Paleologo G.; Pasquariello A.; Marchetti P.; Giannarelli R.; Rindi P.; Navalesi R.; Rizzo G.

Cholesterol levels long term after liver transplant
pp. 2049-2050(2)
Authors: Atillasoy E.; Gurkan A.; Mor E.; Altaca G.; Sheiner P.; Guy S.; Schwartz M.; Miller C.; Berk P.; Emre S.

Additive effect of cyclosporine and low density lipoproteins on transforming growth factor-₁ and monocyte chemotactic protein-1 expression in human mesangial cells
pp. 2051-2051(1)
Authors: Di Paolo S.; Grandaliano G.; Gesualdo L.; Ranieri E.; Schena F.P.

Comparison of serum lipids, lipoproteins, and fibrinogen in patients with kidney transplantation and hemodialysis
pp. 2052-2053(2)
Authors: Demirag A.; Moray G.; Ozdemir N.; Hizel N.; Bilgin N.; Haberal M.

Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients
pp. 2054-2054(1)
Authors: Melchor J.L.; Gracida C.

Cancer in immune-suppressed organ transplant recipients: aetiology and evolution
pp. 2055-2057(3)
Author: Sheil A.G.R.

Difference among races in posttransplant malignancies: report from an oriental country
pp. 2058-2059(2)
Authors: Akiyama T.; Imanishi M.; Matsuda H.; Nishioka T.; Kunikata S.; Kurita T.

Viral infections in organ transplantation
pp. 2060-2063(4)
Authors: Tolkoff-Rubin N.E.; Rubin R.H.

Renal transplantation in patients positive for hepatitis B or C (Pro)
pp. 2064-2069(6)
Author: Morales J.M.

Renal transplantation in patients positive for hepatitis B or C (Con)
pp. 2070-2072(3)
Author: Pereira B.J.G.

Mild course of c hepatitis after long-term follow-up in hepatitis b and c coinfected liver transplant recipients
pp. 2073-2075(3)
Authors: Caccamo L.; Maggi U.; Rossi G.; Damilano I.; Reggiani P.; Melada E.; Ghidoni P.; Paone G.; Gatti S.; Fassati L.R.

Long-term evolution of anti-HCV-positive renal transplant recipients
pp. 2076-2078(3)
Authors: Aroldi A.; Lampertico P.; Elli A.; Lunghi G.; Tarantino A.; Montagnino G.; Colombo M.; Ponticelli C.

Cytomegalovirus infection is a trigger for monoclonal immunoglobulins in paediatric kidney transplant recipients
pp. 2079-2082(4)
Authors: Ginevri F.; Nocera A.; Bonato L.; Losurdo G.; Rossi G.; Mangraviti S.; Fontana I.; Rabagliati A.M.; Basile G.; Barocci S.; Valente U.; Gusmano R.

Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease
pp. 2083-2085(3)
Authors: Waiser J.; Budde K.; Schreiber M.; Korn K.; Stenglein S.; Drenckhahn J.-T.; Bohler T.; Hauser I.; Neumayer H.-H.

Combined human cytomegalovirus and hepatitis C virus infections increase the risk of allograft vascular disease in heart transplant recipients
pp. 2086-2090(5)
Authors: Bello B.D.; Klersy C.; Grossi P.; Gavazzi A.; Ippoliti G.; Rinaldi M.; Vigano M.; Arbustini E.

Human herpes virus-6 or epstein-barr virus infection and acute allograft rejection in pediatric kidney transplant recipients: greater risk for immunologically naive recipients
pp. 2091-2093(3)
Authors: Wade A.W.; McDonald A.T.J.; Acott P.D.; Lee S.; Crocker J.F.S.

Cytomegalovirus disease prophylaxis in renal transplantation by high dose oral acyclovir: efficacy and limits
pp. 2094-2094(1)
Authors: Bertoni E.; Rosati A.; Zanazzi M.; Moscarelli L.; Di Maria L.; Piperno R.; Orsi A.; Parri F.; Dedola G.; Salvadori M.

Posttransplant human herpes virus 8 infection and seroconversion in a kaposi's sarcoma affected kidney recipient transplanted from a human herpes virus 8 positive living related donor
pp. 2095-2096(2)
Authors: Nocera A.; Corbellino M.; Valente U.; Barocci S.; Torre F.; Palma R.D.; Sementa A.; Traverso G.B.; Icardi A.; Fontana I.; Arcuri V.; Poli F.; Cagetti P.; Moore P.; Parravicini C.

Incidence of cytomegalovirus disease in renal transplantation without antilymphocyte induction: is prophylaxis necessary?
pp. 2097-2099(3)
Authors: Smith S.R.; Butterly D.W.; Conlon P.J.; Harland R.C.; Emovon O.E.

Hepatitis C virus infection after renal transplantation: prevalence and course of morphologic lesions
pp. 2100-2101(2)
Authors: Sandrini S.; Chiappini R.; Setti G.; Carli O.; Matricardi L.; Puoti M.; Callea F.; Favret M.; Maiorca R.

Cost analysis of four strategies for prevention of CMV infection in liver transplant recipients
pp. 2102-2103(2)
Authors: Post A.B.; Mulligan D.C.; Bush W.

Treatment of recurrent hepatitis c virus infection after liver transplantation with interferon and ribavirin
pp. 2104-2106(3)
Authors: Gotz G.; Schon M.R.; Haefker A.; Neuhaus R.; Berg T.; Hopf U.; Neuhaus P.

Liver transplantation for viral hepatitis-associated cirrhosis
pp. 2107-2111(5)
Authors: Caccamo L.; Rossi G.; Reggiani P.; Gatti S.; Maggi U.; Paone G.; Fassati L.R.

Bacteremia and endocarditis following endomyocardial biopsy
pp. 2112-2113(2)
Authors: Aziz T.M.; Krysiak P.; El-Gamel A.; Campbell C.; Rahman A.; Deiraniya A.; Isalska B.; Yonan N.

Treatment of bone pain after kidney transplantation
pp. 2114-2116(3)
Authors: Grotz W.; Rump J.A.; Niessen A.; Schmidt-Gayk H.; Schollmeyer P.

Effect of antibiotic treatment with azithromycin on cyclosporine A-induced gingival hyperplasia among renal transplant recipients
pp. 2117-2119(3)
Authors: Wirnsberger G.H.; Pfragner R.; Mauric A.; Zach R.; Bogiatzis A.; Holzer H.

Medication influencing the development of gingival overgrowth in renal transplant patients
pp. 2120-2121(2)
Authors: Varga E.; Mair L.H.

Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia
pp. 2122-2123(2)
Authors: Kohnle M.; Lutkes P.; Witzke O.; Philipp T.; Heemann U.

Role of immunosuppressive therapy in neuroendocrine activation after human heart, renal, and liver transplantation
pp. 2124-2126(3)
Authors: Piquard F.; Geny B.; Elero B.; Canguilhem B.; Mettauer B.; Epailly E.; Chakfe N.; Charpentier A.; Wolf P.; Kretz J.G.; Eisenmann B.; Koehl C.; Haberey P.

Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis
pp. 2127-2128(2)
Authors: Hortal L.; Fernandez A.; Vega N.; Rodrguez J.C.; Losada A.; Lorenzo M.; Plaza C.; Palop L.

Peptide mediated immunosuppression: new developments
pp. 2131-2135(5)
Authors: Magee C.C.; Sayegh M.H.

Persistent allopeptide reactivity and epitope spreading in chronic rejection
pp. 2136-2137(2)
Authors: Suciu-Foca N.; Ciubotariu R.; Liu Z.; Ho E.; Rose E.A.; Cortesini R.

Contribution of the direct and indirect allorecognition pathway to the rejection of liver allografts
pp. 2138-2139(2)
Authors: Renna-Molajoni E.; Cinti P.; Orlandini A.M.; Molajoni J.; Cocciolo P.L.; Evangelista B.; Suciu-Foca N.; Cortesini R.

Role of the indirect recognition pathway in the development of chronic liver allograft rejection
pp. 2140-2141(2)
Authors: Renna-Molajoni E.; Cinti P.; Evangelista B.; Orlandini A.M.; Molajoni J.; Cocciolo P.L.; Suciu-Foca N.; Cortesini R.

Application of antisense oligodeoxynucleotides for organ transplantation - Perspectives for Research and Therapy in the Late 1990s
pp. 2142-2145(4)
Author: Stepkowski S.M.

Blocking T-cell costimulation to prevent transplant rejection
pp. 2146-2149(4)
Authors: Zheng X.-G.; Turka L.A.

Reversal of acute allograft rejection using immunotoxin
pp. 2150-2151(2)
Authors: Knechtle S.J.; Fechner Jr J.H.; Stavrou S.; Neville Jr D.M.; Dong Y.; Hong X.; Tsuchida M.; Hamawy M.M.

Relative affinity of chi 621 for t-cell blasts of humans, rhesus, cynomolgus monkeys and dogs
pp. 2152-2154(3)
Authors: Quesniaux V.F.J.; Vedrine C.; Maurer C.; Grossmueller F.; Schuurman H.-J.; Schreier M.H.; Mueller K.

Daclizumab: outcome of phase III trials and mechanism of action
pp. 2155-2158(4)
Authors: Vincenti F.; Nashan B.; Light S.

Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation
pp. 2159-2160(2)
Authors: Glanemann M.; Langrehr J.M.; Raakow R.; Guckelberger O.; Lohmann R.; Klupp J.; Lobeck H.; Schlag H.; Keck H.; Bechstein W.O.; Settmacher U.; Neuhaus P.

Selective immunosuppression with fk 506, anti-il-2r, and anti-icam-1 monoclonal antibodies: contrasting effects after liver and small bowel transplantation in rats
pp. 2161-2162(2)
Authors: Otto C.; Gasser M.; Gassel H.-J.; Steger U.; Timmermann W.; Meyer D.; Ulrichs K.; Thiede A.

Anti-LFA-1 monoclonal antibody in renal transplantation: renal function, infections, and other complications
pp. 2163-2163(1)
Authors: Spillner J.; Kohnle M.; Albrecht K.-H.; Heemann U.

Preliminary results from a randomized and prospective study of high-dose immunoglobulin versus monoclonal antibody in the rescue of steroid-resistant rejections
pp. 2164-2164(1)
Authors: Casadei D.; Rial M.; Argento J.; Goldberg J.; Raimondi E.

Blocking of costimulation prevents kidney graft rejection in rhesus monkeys
pp. 2165-2166(2)
Authors: Ossevoort M.A.; Ringers J.; Boon L.; Lorre K.; van den Hout Y.; Kuhn E.-M.; de Boer M.; Jonker M.; de Waele P.

Calcineurin and the biological effect of cyclosporine and tacrolimus
pp. 2167-2170(4)
Authors: Halloran P.F.; Kung L.; Noujaim J.

Tacrolimus (FK 506) in kidney transplantation
pp. 2171-2173(3)
Author: Vanrenterghem Y.

Tacrolimus is superior to cyclosporine in liver transplantation
pp. 2174-2178(5)
Authors: Busuttil R.W.; Holt C.D.

Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation
pp. 2179-2181(3)
Authors: Jonas S.; Guckelberger O.; Bechstein W.O.; Berg T.; Muller A.R.; Platz K.P.; Tullius S.G.; Settmacher U.; Steinmuller T.; Hopf U.; Neuhaus P.

Study of the immunosuppressive effect of SMS 201-995 and its synergic action with FK 506
pp. 2182-2184(3)
Authors: Perego C.; Lattuada D.; Casnici C.; Gatti S.; Orsenigo R.; Panagiotis S.; Franco P.; Marelli O.

Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients
pp. 2185-2188(4)
Author: Kahan B.D.

Role of therapeutic drug monitoring of rapamycin
pp. 2189-2191(3)
Authors: Kahan B.D.; Napoli K.L.

Chemical modification of rapamycin: the discovery of SDZ RAD
pp. 2192-2194(3)
Authors: Sedrani R.; Cottens S.; Kallen J.; Schuler W.

The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation
pp. 2195-2197(3)
Authors: Bohler T.; Waiser J.; Budde K.; Lichter S.; Jauho A.; Fritsche L.; Korn A.; Neumayer H.-H.

The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation
pp. 2198-2199(2)
Authors: Schuurman H.-J.; Schuler W.; Ringers J.; Jonker M.

Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model
pp. 2200-2203(4)
Authors: Cole O.J.; Shehata M.; Rigg K.M.

Effects of rapamycin analogue SDZ RAD on obliterative lesions in a porcine heterotopic bronchial allograft model
pp. 2204-2205(2)
Authors: Salminen U.S.; Alho H.; Taskinen E.; Maasilta P.; Ikonen T.; Harjula A.L.J.

In vitro biotransformation of SDZ RAD: a new immunosuppressive macrolide in human liver microsomal preparations
pp. 2206-2206(1)
Authors: Dannecker R.; Vickers A.E.M.; Ubeaud G.; Hauck C.

Tracheal allograft transplantation in rats: the role of immunosuppressive agents in development of obliterative airway disease
pp. 2207-2209(3)
Authors: Yonan N.A.; Bishop P.; El-Gamel A.; Hutchinson I.V.

FTY720: a new immunosuppressive agent with novel mechanism(s) of action
pp. 2210-2213(4)
Author: Kahan B.D.

Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival
pp. 2214-2216(3)
Authors: Stepkowski S.M.; Wang M.-e.; Qu X.; Yu J.; Okamoto M.; Tejpal N.; Kahan B.D.

FTY720 inhibits the mRNA expression of intragraft cytotoxic molecules, leading to cardiac allograft survival
pp. 2217-2220(4)
Authors: Nakajima H.; Sun E.; Mizuta N.; Fujiwara I.; Oka T.

FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation
pp. 2221-2222(2)
Authors: Xu M.; Pirenne J.; Antoniou S.; Gunson B.; D'silva M.; McMaster P.

Mycophenolate mofetil, tacrolimus, neoral: from clinical trials to the clinic
pp. 2223-2225(3)
Author: Pirsch J.D.

Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes
pp. 2226-2227(2)
Authors: Puig J.M.; Lloveras J.; Fernandez-Crespo P.; Mir M.; Marcas L.I.; Manresa J.M.; Masramon J.

Tolerance of mycophenolate mofetil is dependent on kidney function
pp. 2228-2228(1)
Authors: Puggia R.; Rizzolo M.; Maresca M.-C.; Calconi G.; Vianello A.

Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function
pp. 2229-2229(1)
Authors: Fritsche L.; Sperschneider H.; Budde K.; Giessing M.; Turk H.; Bohler T.; Schroder K.; Stein G.; Neumayer H.-H.

Mycophenolate mofetil and reduction in cyclosporine dosage for chronic renal allograft dysfunction
pp. 2230-2231(2)
Authors: Islam M.S.; Francos G.C.; Dunn S.R.; Burke J.F.

Indication for mycophenolate mofetil therapy in hepatitis c patients undergoing liver transplantation
pp. 2232-2233(2)
Authors: Platz K.-P.; Mueller A.R.; Willimski C.; Mansoorian B.; Berg T.; Neuhaus R.; Hopf U.; Radke C.; Neuhaus P.

Scientific principles for mycophenolic acid therapeutic drug monitoring - Measuring Variability in Response, Concentration and Dose
pp. 2234-2236(3)
Authors: Shaw L.M.; Korecka M.; Aradhye S.; Grossman R.; Barker C.; Naji A.; Brayman K.L.

Pharmacokinetics of mycophenolic acid after renal transplantation
pp. 2237-2239(3)
Authors: Wollenberg K.; Krumme B.; Schollmeyer P.; Kirste G.

Brequinar and brequinar analogues in rat allo- and xenotransplantation - Developments in Anti-Rejection Therapy
pp. 2240-2243(4)
Authors: Schuurman H.-J.; Tanner M.; Pally C.; Jaffee B.D.

Brequinar sodium and liver hemoperfusion in xenotransplantation
pp. 2244-2245(2)
Authors: Chastanet S.; Cursio R.; Gugenheim J.; Baldini E.; Chevallier A.; Damais A.; Charpentier B.; Mouiel J.

Beneficial effects of 15-deoxyspergualin on late acute rejection occurring more than three months after renal transplantation
pp. 2246-2247(2)
Authors: Amada N.; Okazaki H.; Sato T.; Miura S.; Ohashi Y.

Photopheresis in transplantation: future research and directions
pp. 2248-2250(3)
Author: Barr M.L.

Donor action: a systematic approach to organ donation
pp. 2253-2254(2)
Authors: Wight C.; Cohen B.; Beasley C.; Miranda B.; Deblander G.

Issues in organ donation: living unrelated kidney transplantation
pp. 2255-2258(4)
Authors: Alfani D.; Bruzzone P.; Pretagostini R.; Poli L.; Cortesini R.

Issues in organ transplantation
pp. 2259-2260(2)
Author: Van Buren C.T.

Recipient and donor outcomes in living related and unrelated lobar transplantation
pp. 2261-2263(3)
Authors: Barr M.L.; Schenkel F.A.; Cohen R.G.; Barbers R.G.; Fuller C.B.; Hagen J.A.; Wells W.J.; Starnes V.A.

Living versus cadaver donor pancreas transplants
pp. 2264-2266(3)
Authors: Sutherland D.E.R.; Najarian J.S.; Gruessner R.

Living-related donor liver transplantation - Ethics, Justice, Commerce
pp. 2267-2268(2)
Authors: Haberal M.; Bilgin N.; Arslan G.; Karakayali H.; Akpinar E.; Moray G.; Varan B.; Turan M.; Boyacioglu S.

Elderly and other suboptimal renal grafts and transplant outcome
pp. 2269-2271(3)
Author: Lloveras J.

Renal transplantation from suboptimal donors
pp. 2272-2273(2)
Authors: Sanchez-Fructuoso A.I.; Prats D.; Naranjo P.; Fernandez C.; Aviles B.; Herrero J.A.; Barrientos A.

Long-term function and survival rates of kidneys from extreme-age donors in the cyclosporine era
pp. 2274-2275(2)
Authors: Ferraresso M.; Berardinelli L.; Bellapi A.; Vegeto A.

Elderly donors (60 to 87 years) in renal transplantation: good results after 5 years
pp. 2276-2276(1)
Authors: Guirado L.; Sola R.; Agraz I.; Daz M.; Vila A.; Paredes D.; Vizcarra D.; Barcelo P.

Renal transplantation in elderly patients
pp. 2277-2278(2)
Authors: Sanchez-Fructuoso A.I.; Prats D.; Naranjo P.; Fernandez C.; Aviles B.; Barrientos A.

Elderly donors in renal transplantation: a worthwhile venture?
pp. 2279-2279(1)
Authors: Lewis D.M.; Gorrie M.; Bingham C.; Nichols A.J.; Beaman M.; Riad H.N.

Outcome of renal transplants using cadaveric paediatric donors in three countries
pp. 2280-2282(3)
Authors: Pugliese M.R.; De Luca J.; Hollenbeck M.; Grabensee B.; Heering P.J.

Long-term follow-up of renal donors
pp. 2283-2285(3)
Authors: Undurraga A.; Roessler E.; Arcos O.; Gonzalez F.; Espinoza O.; Herrera S.; Ayala A.; Reynolds E.; Espinoza M.; Hidalgo F.

Limitation in selection of donors in a living-related renal transplant programme
pp. 2286-2288(3)
Authors: Naqvi S.A.A.; Mazhar F.; Ahmed R.; Jamal H.; Zaidi R.; Rizvi A.

Domino (crossover) kidney transplantation using low doses of neoral
pp. 2289-2290(2)
Authors: Juarez F.; Barrios Y.; Cano L.; Chavez E.; Camacho R.; Gomez A.; Maciel M.; Borjon S.; Limones M.; Peniche L.

Influence of CsA therapy on the outcome of kidneys with anatomic anomalies
pp. 2291-2292(2)
Authors: Berardinelli L.; Carini M.; Beretta C.; Vegeto A.

Is there a different impact of cyclosporine versus tacrolimus on delayed graft function after kidney transplantation?
pp. 2293-2293(1)
Authors: Hanack U.; Lorf T.; Braun F.; Grupp C.; Sattler B.; Binder L.; Muller G.A.; Ringe B.

Value of backtable angioscopy previous to kidney transplantation
pp. 2294-2294(1)
Authors: Burgos F.J.; Marcen R.; Pascual J.; Gomez V.; Teruel J.L.; Cano M.T.; Ortuno J.

Partial nephrectomy with in situ perfusion preservation for renal cell carcinoma in a long established renal transplant
pp. 2295-2297(3)
Authors: Merkel F.K.; Miller J.L.; Hibblen J.F.; Owens C.J.

Immunologic low-responder in ABO-incompatible renal transplant recipients explored by donor-specific platelet transfusion
pp. 2298-2299(2)
Authors: Ishibashi M.; Oshida M.; Kurata Y.; Kokado Y.; Takahara S.; Kyo M.; Ikoma F.

Role of tissue factor in ischemic reperfusion injury: iv) the effect of tissue factor pathway inhibitor on the survival rate in vivo
pp. 2300-2301(2)
Authors: Yoshimura N.; Kobayashi Y.; Nakamura K.; Yoshimura R.; Yamagishi H.; Oka T.

Abo-incompatible renal transplantation-dissociation of abo antibodies
pp. 2302-2303(2)
Authors: Uchida K.; Tominaga Y.; Haba T.; Katayama A.; Ichimori T.; Yamada K.; Hibi Y.; Oikawa T.; Takeda A.; Morozumi K.; Takagi H.

Graft versus host antibody reactions in abo unmatched renal transplants
pp. 2304-2305(2)
Authors: Bertoni E.; Rosati A.; Zanazzi M.; Moscarelli L.; Di Maria L.; Tosi P.; Bandini S.; Salvadori M.

The effect of low dose epinephrine infusion on hepatic hemodynamics
pp. 2306-2308(3)
Authors: Marsh J.W.; Drougas J.G.; Wright J.K.; Chapman W.C.; Becker Y.T.; Barnard S.E.; Donovan K.L.; Feurer I.; Sika M.; Blair K.T.; Hamilton K.A.; Pinson C.W.

Identification of kidneys subjected to pre-retrieval warm ischemic injury during hypothermic perfusion preservation
pp. 2309-2310(2)
Authors: Inman S.; Osgood R.; Plott W.; Richardson B.; Lewis R.

Transplantation-induced ischemia/reperfusion injury in the rat heart
pp. 2311-2313(3)
Authors: Bigaud M.; Gfeller P.; Deveze S.; Vogt G.; Evenou J.P.; Bruns C.; Zerwes H.G.

Influence of cold and warm ischemia on amino acid profiles after liver transplantation
pp. 2314-2316(3)
Authors: Schon M.R.; Heil W.; Benckert C.; Matthes M.; Akkoc N.; Kollmar O.; Wolf S.; Neuhaus P.

Ischemia-reperfusion injury in a diet-induced rat fatty liver
pp. 2317-2317(1)
Authors: Nardo B.; Domenicali M.; Caraceni P.; Turi P.; Dall'Agata M.; Mazziotti A.; Bernardi M.; Cavallari A.

Cold ischemia affects sinusoidal endothelial cells while warm ischemia affects hepatocytes in liver transplantation
pp. 2318-2320(3)
Authors: Schon M.R.; Kollmar O.; Akkoc N.; Matthes M.; Wolf S.; Schrem H.; Tominaga M.; Keech G.; Neuhaus P.

Hepatic ischemia-reperfusion injury causes E-selectin upregulation
pp. 2321-2323(3)
Authors: Burke J.; Zibari G.B.; Brown M.F.; Granger N.; Kelly R.; Singh I.; McDonald J.C.

Anti-P-selectin antibody protects against hepatic ichemia-reperfusion injury
pp. 2324-2326(3)
Authors: Singh I.; Zibari G.B.; Zizzi H.; Granger D.N.; Cruz L.; Gonsales E.; McDonald J.C.; Brown M.F.

Role of P-selectin in the recruitment of leukocytes in mouse liver exposed to ischemia and reperfusion
pp. 2327-2330(4)
Authors: Zibari G.B.; Brown M.F.; Burney D.L.; Granger N.; McDonald J.C.

Impact of donor factors on postoperative liver function after orthotopic rat liver transplantation
pp. 2331-2333(3)
Authors: Neumann U.; Knoop M.; Langrehr J.M.; Lang M.; Neuhaus P.

Effects of epoprostenol and norepinephrine on hemodynamics of the isolated perfused liver
pp. 2334-2335(2)
Authors: Wolf S.; Schon M.R.; Krautlein K.; Rossaint R.; Kaisers U.; Neuhaus P.; Falke K.J.

l-Arginine application improves mucosal structure after small bowel transplantation
pp. 2336-2338(3)
Authors: Mueller A.R.; Platz K.-P.; Heckert C.; Hausler M.; Radke C.; Neuhaus P.

Lessons from rat models on the genetic basis of interindividual differences in lymphocyte phenotype
pp. 2341-2343(3)
Authors: Wonigeit K.; Washington D.; Hundrieser J.

CTL effector mechanisms: diagnostic applications
pp. 2344-2346(3)
Authors: Schachter A.D.; Vasconcellos L.; Ophascharoensuk V.; Zheng X.X.; Strehlau J.; Strom T.B.

Expression of granzyme B, perforin and TIA-1 in urine lymphocytes: noninvasive monitoring of renal transplant function
pp. 2347-2347(1)
Authors: Barth C.; Rodermann E.; Stachowski J.; Herzog R.; Rohde S.; Baldamus C.A.

Activation-dependent lymphocyte apoptosis induced by methotrexate
pp. 2348-2350(3)
Authors: Paillot R.; Genestier L.; Fournel S.; Ferraro C.; Miossec P.; Revillard J.P.

Targeting T cell killing with complement component C3-anti CD3 fusion proteins - A Laboratory Manual, 2nd ed
pp. 2351-2352(2)
Authors: Fecke W.; Koukidou M.; Farries T.C.; Harrison R.A.

T-cell apoptosis following renal transplantation
pp. 2353-2354(2)
Authors: Kasprzycka M.; Gorski A.; Nowaczyk M.; Korczak-Kowalska G.; Wierzbicki P.; Durlik M.; Wyzgal J.; Gradowska L.; Lao M.

Caspase requirement for the apoptotic death of WR19L-induced by FTY720
pp. 2355-2357(3)
Authors: Matsuda T.; Nakajima H.; Fujiwara I.; Mizuta N.; Oka T.

Apoptosis and the expression of Fas and Fas-ligand antigen after orthotopic liver transplantation
pp. 2358-2359(2)
Authors: Tannapfel A.; Kohlhaw K.; Schwarz R.; Wenzke M.; Kockerling F.; Ebelt J.; Hauss J.; Wittekind C.

Spontaneous liver graft acceptance is mediated by intragraft fas-ligand expression and viable passenger leukocytes
pp. 2360-2361(2)
Authors: Fandrich F.; Lin X.; Zhu X.; Parwaresch R.; Kremer B.; Henne-Bruns D.

Apoptosis as an instrument for immune regulation: study on a liver/small bowel tolerant rat model
pp. 2362-2363(2)
Authors: Meyer D.; Thorwarth M.; Otto C.; Gasser M.; Gassel H.-J.; Timmermann W.; Ulrichs K.; Thiede A.

Molecular correlates of human renal allograft rejection
pp. 2364-2366(3)
Authors: Sharma V.K.; Ding R.; Li B.; Bologa R.M.; Lagman M.; Eduafo A.; Edouard P.; Mouradian J.; Strom T.B.; Suthanthiran M.

Polymerase chain reaction methods in immunology
pp. 2367-2369(3)
Author: Dallman M.J.

Quantitative competitive polymerase chain reaction: design and synthesis of mRNA-specific competitor DNA templates and their clinical usage
pp. 2370-2372(3)
Authors: Ding R.; Li B.; Sharma V.K.; Bologa R.M.; Lagman M.; Mouradian J.; Strom T.B.; Suthanthiran M.

Th1/Th2 balance in human disease
pp. 2373-2377(5)
Authors: D'Elios M.; Del Prete G.

Cyclosporine A is associated with a shift of the TH1/TH2 balance in liver transplant patients
pp. 2378-2379(2)
Authors: van den Berg A.P.; Twilhaar W.N.; Corver K.; Geerts A.B.; Mesander G.; Klompmaker I.J.; Slooff M.J.H.; The T.H.; de Leij L.H.F.M.

Immunohistochemical quantification of leukocyte subsets in the long-term prognosis of kidney transplants
pp. 2380-2383(4)
Authors: Vergara E.; Gomez-Morales M.; Osuna A.; O'Valle F.; Aguilar D.; Masseroli M.; Martnez T.; Higueras M.; Bravo J.; Asensio C.; Del Moral R.G.

Study of lymphocyte costimulatory molecules in renal transplantation
pp. 2384-2386(3)
Authors: Biancone L.; Donati D.; Segoloni G.; Turello E.; Squiccimarro G.; Bussolati B.; Cantaluppi V.; Amann F.; Gastaldi L.; Piccoli G.; Camussi G.

Interleukin-10 and cellular rejection following cardiac transplantation
pp. 2387-2388(2)
Authors: El Gamel A.; Grant S.; Yonan N.; Keevil B.; Aziz T.; Deiraniya A.K.; Campbell C.; Rahman A.; Haselton P.; Hutchinson I.V.

Adjusting immunosuppression to the identification of t-cell activating mediators in rejecting transplants: a novel approach to rejection diagnosis and treatment
pp. 2389-2391(3)
Authors: Strehlau J.; Maslinski W.; Chae D.; Pavlakis M.; Ehrich J.H.H.; Strom T.B.

Flow cytometric detection of IL-6 production by CD14+ cells: the effect of in vitro addition of cyclosporine-A and prednisolone
pp. 2392-2394(3)
Authors: Degiannis D.; Kapsalis A.; Thalassinos A.; Koniavitou K.

Cytokine-regulated expression of vascular cell adhesion molecule-1 in human glomerular endothelial cells
pp. 2395-2397(3)
Authors: Park S.; Chang Y.H.; Cho Y.J.; Ahn H.; Yang W.S.; Park J.S.; Lee J.D.

Diagnostic relevance of procalcitonin, IL-6 and cellular immune status in the early phase after liver transplantation
pp. 2398-2399(2)
Authors: Kunz D.; Pross M.; Konig W.; Lippert H.; Manger T.

Flow cytometry detection of intracytoplasmic cytokines after neoral or sirolimus intake is an informative tool for monitoring in vivo immunosuppressive efficacy in renal transplant recipients
pp. 2400-2401(2)
Authors: Tkaczuk J.; Rostaing L.; Puyoo O.; Peres C.; Abbal M.; Durand D.; Ohayon E.

Chronic rejection: increasing evidence for the importance of allogen-independent factors
pp. 2402-2406(5)
Authors: Wilhelm M.J.; Kusaka M.; Pratschke J.; Tilney N.L.

Chronic rejection: risk factors, regulation, and possible sites of therapeutic intervention
pp. 2407-2410(4)
Author: Hayry P.

Synergistic mechanisms of alloantigen-dependent and independent events in chronic graft rejection
pp. 2411-2412(2)
Authors: Tullius S.G.; Nieminen M.; Qun Y.; Egermann F.; Reutzer-Selke A.; Jonas S.; Pratschke J.; Bechstein W.O.; Volk H.D.; Neuhaus P.

Chronic graft loss: dealing with the vascular alterations in solid organ transplantation
pp. 2413-2418(6)
Authors: Cook N.S.; Zerwes H.-G.; Rudin M.; Beckmann N.; Schuurman H.-J.

Rejection after kidney transplantation: new concepts, new therapeutic options
pp. 2419-2424(6)
Authors: van der Woude F.J.; Hollander A.A.M.J.

P-glycoprotein expression in acute kidney graft rejection
pp. 2425-2426(2)
Authors: Vergara E.; Gomez-Morales M.; Ramrez C.; Osuna A.; Olmo A.; O'Valle F.; Saez A.I.; Alvarez G.; Palomares M.; Aguilar M.; Bravo J.; Asensio C.; Del Moral R.G.

Progress in the induction of tolerance to allografts
pp. 2427-2429(3)
Author: Morris P.J.

Mechanisms of unresponsiveness to alloantigens in vivo
pp. 2430-2431(2)
Author: Wood K.J.

Use of pharmacologic immunosuppression to augment the specific unresponsiveness (tolerance) to skin allografts induced by donor-specific bone marrow in antilymphocyte serum-treated mice: the unique effect of sirolimus
pp. 2432-2434(3)
Authors: Hale D.; Gottschalk R.; Maki T.; Monaco A.P.

Experimental and clinical tolerance induction
pp. 2435-2437(3)
Authors: Hardy M.A.; Agrawal S.; Suciu-Foca N.

Donor-specific transfusion-induced tolerance: mechanisms revisited
pp. 2438-2440(3)
Author: Soulillou J.-P.

Induction of kidney graft acceptance by creating a window of opportunity for immunologic engagement (WOFIE) in rhesus monkeys
pp. 2441-2443(3)
Authors: Jonker M.; Slingerland W.; Ossevoort M.; Kuhn E.; Neville D.; Friend P.; Calne R.

Improved skin allograft tolerance induced by treatment with donor splenocytes and an extended course of anti-CD154 monoclonal antibody
pp. 2444-2446(3)
Authors: Markees T.; Phillips N.; Gordon E.; Noelle R.J.; Mordes J.P.; Greiner D.L.; Rossini A.A.

Fine tuning of antigen-presenting cell-directed monoclonal antibody strategies in the induction of human allospecific T-cell tolerance in vitro
pp. 2447-2449(3)
Authors: Koenen H.J.P.M.; Joosten I.

Immunogenic (MHC class II⁺) cells are able to induce unresponsiveness when delivered with anti-CD4 monoclonal antibody
pp. 2450-2450(1)
Authors: Niimi M.; Morris P.J.; Wood K.J.

Complete withdrawal of immunosuppression in kidney allograft recipients: a prospective study in rhesus monkeys
pp. 2451-2453(3)
Authors: Jonker M.; van den Hout Y.; Neuhaus P.; Ringers J.; Kuhn E.M.; Bruijn J.A.; Schuurman H.J.; Noort R.; Bontrop R.E.; Claas F.H.J.; van Rood J.J.

Donor spleen cell isolation for augmentation of donor-cell chimerism in organ transplantation
pp. 2454-2455(2)
Authors: Risaliti A.; Corno V.; Baccarani U.; Ermacora A.; Cautero N.; Donini A.; Anania G.; Bresadola F.

Strategies to prevent thrombosis in xenotransplants
pp. 2458-2460(3)
Authors: Levy G.A.; Marsden P.; Zhong R.; Cole E.H.; Grant D.

The safety of xenotransplantation
pp. 2461-2462(2)
Author: Cooper D.K.C.

Ethical aspects in xenotransplantation
pp. 2463-2464(2)
Author: Cortesini R.

Kidneys from HDAF transgenic pigs are physiologically compatible with primates
pp. 2465-2466(2)
Authors: Zaidi A.; Bhatti F.; Schmoeckel M.; Cozzi E.; Chavez G.; Wallwork J.; White D.; Friend P.

Survival of life-supporting HDAF transgenic kidneys in primates is enhanced by splenectomy
pp. 2467-2467(1)
Authors: Bhatti F.N.K.; Zaidi A.; Schmoeckel M.; Cozzi E.; Chavez G.; Wallwork J.; White D.J.G.; Friend P.J.

Variation in porcine red blood cell -galactosyl expression and agglutination by human serum
pp. 2468-2468(1)
Authors: MacLaren L.; Lee T.D.G.; Anderson D.; Nass M.; McAlister V.C.

Bioartificial liver based on porcine hepatocyte: in vitro functional assessment
pp. 2469-2470(2)
Authors: Corno V.; Donini A.; Vianello V.; Gonano C.; Bonfreschi V.; Pasqualotto A.; Risaliti A.; Belvedere O.; Degrassi A.; Bresadola F.

Selection of donor pigs for pancreatic islet transplantation may depend on the expression level of connective tissue proteins in the islet capsule
pp. 2471-2473(3)
Authors: Meyer T.; Buhler C.; Czub S.; Beutner U.; Otto C.; Thiede A.; Ulrichs K.

Effect of cryopreservation on Gal1-3Gal expression on adult porcine pancreatic islets
pp. 2474-2474(1)
Authors: Papalois V.E.; Berwanger C.; Romagnoli J.; Lee J.; Cleanthis T.; Robinson J.; Cairns T.; Stansby G.; Taube D.; Hakim N.S.

Traumatized pigs are unsuitable as organ donors for pancreatic islet isolation
pp. 2475-2477(3)
Authors: Meyer T.; Buhler C.; Debus S.; Beutner U.; Otto C.; Timmermann W.; Tsapenko N.; Hamelmann W.; Thiede A.; Ulrichs K.

Xenotransplantation of bovine islets into the thymus of totally pancreatectomized pigs
pp. 2478-2480(3)
Authors: Carmellini M.; Del Guerra S.; Solari R.; Marchetti P.; Bellissima G.; Meacci L.; Burchielli S.; Giannarelli R.; Calabrese M.; Navalesi R.; Mosca F.

Corticotropin-releasing hormone facilitates early survival of discordant (bovine-to-rat) islet xenografts
pp. 2481-2483(3)
Authors: Lupi R.; Marchetti P.; Coppelli A.; Giannarelli R.; Petraglia F.; Luisi S.; Del Guerra S.; Tellini C.; Florio P.; Genazzani A.; Viacava P.; Navalesi R.

Development of xenogeneic microchimerism correlated with graft outcome in hamster-to-rat heart xenotransplantation
pp. 2484-2485(2)
Authors: Miyata Y.; Ohdan H.; Noriyuki T.; Shintaku S.; Shibata S.; Yamamoto H.; Fudaba Y.; Fan X.H.; Tashiro H.; Yoshioka S.; Asahara T.; Fukuda Y.; Dohi K.

Prolongation of graft survival in the concordant hamster-to-rat cardiac model
pp. 2486-2487(2)
Authors: Brouard S.; Blancho G.; Moreau A.; Heslan J.-M.; Cuturi M.-C.; Soulillou J.P.

Fas and Fas ligand in discordant xenogeneic antibody-dependent cell-mediated cytotoxicity - A User's Guide
pp. 2488-2490(3)
Authors: Fujiwara I.; Nakajima H.; Matsuda T.; Mizuta N.; Yamagishi H.; Oka T.

Renaissance of immunosuppressive therapy in the new millennium
pp. 2493-2496(4)
Author: Kahan B.D.